Nanomaterial Design for Macrophage Reprogramming: Emerging Strategies and Mechanistic Insights for Inflammation and Tumor Therapy
- 20 October 2026
- journal article
- review article
- Published by American Chemical Society (ACS) in ACS Applied Bio Materials
- Vol. 9 (21) , 10063-10089
Abstract
Macrophages play a paradoxical role in inflammation and tumor. They can protect the host during acute inflammation but act as the main driver for the chronic inflammation which is a common characteristic of several diseases including rheumatoid arthritis, atherosclerosis, type 2 diabetes, inflammatory bowel disease, and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease. In the tumor microenvironment, macrophages switch their phenotype to the immunosuppressive M2 state that promotes tumor growth, angiogenesis, and metastasis. Emerging nanomaterial platforms are trying to offer transformative solutions by enabling the precise delivery of immunomodulatory drugs directly to disease-site macrophages. This review will provide comprehensive comparative analysis of these emerging nanomaterial designs strategies across two disease paradigms: inflammatory diseases and tumor. The discussion will focus on various strategies which include inhibiting chemokine axis (CCL2-CCR2 axis), selective elimination of macrophages through apoptosis, metabolic reprogramming, biomimetic and apoptotic cell-inspired nanoparticles leveraging natural macrophage clearance pathways to promote M2 polarization in inflammation, and the activation of tumor-associated macrophages via TLR and STING agonist. We highlight the role of nanoparticle surface chemistry, composition, and targeting ligands in achieving the two opposite therapeutic outcomes of these two diseases while maintaining some common design principles including EPR-mediated accumulation at the disease sites and biomimetic modifications. We also mentioned novel next-generation nanoparticle-based platforms that are currently in clinical trials for the treatment of tumor and inflammatory diseases. Finally, we discuss the barriers that limit the clinical translational potential of broad nanoparticles, with particular emphasis on nanoparticle-related immunotoxicity, macrophage heterogeneity, and manufacturing reproducibility of the nanoparticles.Keywords
This publication has 153 references indexed in Scilit:
- Tumor Microenvironment‐Responsive Nanoparticles Enhance IDO1 Blockade Immunotherapy by Remodeling Metabolic ImmunosuppressionAdvanced Science, 2024
- Surface Molecularly Engineered Mitochondria Conduct Immunophenotype Repolarization of Tumor‐Associated Macrophages to Potentiate Cancer ImmunotherapyAdvanced Science, 2024
- Cell Membrane‐Coated Nanoparticles: A New Frontier in ImmunomodulationAdvanced NanoBiomed Research, 2024
- PEGylated therapeutics in the clinicBioengineering & Translational Medicine, 2023
- Role of tumor microenvironment in cancer progression and therapeutic strategyCancer Medicine, 2023
- Polymersomes‐Mediated Delivery of CSF1R Inhibitor to Tumor Associated Macrophages Promotes M2 to M1‐Like Macrophage RepolarizationMacromolecular Bioscience, 2022
- Macrophages as a “weapon” in anticancer cellular immunotherapyThe Kaohsiung Journal of Medical Sciences, 2021
- mRNA Delivery of a Bispecific Single‐Domain Antibody to Polarize Tumor‐Associated Macrophages and Synergize Immunotherapy against Liver MalignanciesAdvanced Materials, 2021
- The Role of Chronic Inflammation in Various Diseases and Anti‐inflammatory Therapies Containing Natural ProductsChemMedChem, 2021
- Targeted systemic dendrimer delivery of CSF‐1R inhibitor to tumor‐associated macrophages improves outcomes in orthotopic glioblastomaBioengineering & Translational Medicine, 2020